Clinical trials: Covid19- Coronavirus- Sars-cov-2
Determine Effect of Urological Malpractice During Covid 19 on Patient Complications
The Impact of Covid 19 Pandemic on Ureteric Stents Complications.
The pandemic of coronavirus disease 2019 (COVID-19) has serious implications on urology practice and raises particular questions for urologists about the management of different conditions.
- Trial name
- NCT05839249
- Testing
- JJ urological stents
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- South Valley University
Long COVID
Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation.
This pilot investigation will recruit people with Long COVID to participate in a 4 week individualized inspiratory muscle training intervention with pre and post spirometry testing and additional functional outcomes to assess the…
- Trial name
- NCT06091358
- Testing
- PrO2
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- University of Bath
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Study of Varespladib in Patients Hospitalized With Severe COVID-19
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in addition to standard of care, in patients…
- Trial name
- STAIRS (NCT04969991)
- Testing
- Varespladib
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ophirex, Inc.
COVID-19
Non Invasive Positive Pressure Ventilation to Minimize Aerosolization for COVID 19
Patients presenting to the emergency department, or needing hospitalization, for a variety of medical conditions often require non-invasive ventilation (breathing support).
- Trial name
- NCT04344925
- Testing
- Aerosol-reducing Mask, Standard Mask
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Immunocompromised Patients
Immunocompromised Swiss Cohorts Based Trial Platform
This study is to set up a flexible trial platform using two existing national cohorts of immunocompromised patients (i.e. Swiss HIV Cohort Study [SHCS] and Swiss Transplant Cohort Study [STCS]) to assess the comparative…
- Trial name
- COVERALL (NCT04805125)
- Testing
- Moderna COVID-19 Vaccine, mRNA-1273 (100 μg), Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)
- Where
- 4 sites in Switzerland
- Volunteers
- 610 people
- Sponsor
- University Hospital, Basel, Switzerland
COVID-19
A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults ⩾18 years.
- Trial name
- NCT04758273
- Testing
- medium dosage inactivated SARS-CoV-2 vaccine, high dosage inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Covid19, Hospitalization
Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients
The primary objective of this study is to evaluate the current management approach with "intermediate" or "therapeutic" doses of tinzaparin for thromboprophylaxis in hospitalized patients, non on ICU organ support, with confirmed…
- Trial name
- INTERACT (NCT05036824)
- Testing
- tinzaparin
- Where
- 7 sites in Greece
- Volunteers
- 300 people
- Sponsor
- University Hospital of Patras
SARS-CoV2 Infection
TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood
The purpose of this study is to determine if the TekiTrust Enzyme-Linked Immunosorbent Assay (ELISA) Kit and TekiTrust Rapid Test can accurately determine the amount of antibodies to fight the COVID-19 virus in sampled blood…
- Trial name
- NCT05338762
- Where
- 5 sites in United States
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- MiCo BioMed Co., Ltd.
COVID-19
Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19
This is Phase 2 multi-center controlled randomized study to assess the efficacy and safety of MIR 19® via 14 days of treatment of participants with symptomatic moderate COVID-19.
- Trial name
- NCT05184127
- Testing
- MIR 19 ®, Standard COVID-19 therapy
- Where
- Russia
- Volunteers
- 156 people
- Sponsor
- National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
CORONAVIRUS INFECTIONS
Effect of a Vaccination Against COVID-19 on Monocyte Production of Oxygenated Derivatives.
Knowing that the vaccine antigen includes the ACE2 binding moiety (RBD), the hypothesis is that circulating vaccine antigen could reduce the enzymatic activity of ACE2, and thus increase circulating AngII concentration, monocyte…
- Trial name
- VACTICOV2 (NCT05655351)
- Testing
- anti-SARS-Cov-2 vaccination
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Covid19
Assessing Testing Strategies for Safe Return to K-12 Schools in an Underserved Population
The primary goal of this study is to determine the most effective SARS-CoV-2 testing strategy for successful return of in-person school in the under-served communities of St. Louis.
- Trial name
- NCT04875520
- Testing
- Screening testing strategy, No screening testing strategy
- Where
- 5 sites in United States
- Volunteers
- 1,390 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
SARS-CoV Infection
Oral Manifestation in Patients With SARS-CoV2 Infection.
The oral cavity is particularly susceptible to viral infection with several viruses such as herpes simplex virus, cytomegalovirus and Zika virus because of its structures, especially salivary glands and soft tissues Moreover…
- Trial name
- NCT04821986
- Where
- Egypt
- Volunteers
- 583 people
- Sponsor
- Fayoum University
Respiratory Distress Syndrome, Adult, Sars-CoV2
Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS
Acute Respiratory Distress Syndrome (ARDS) is a serious condition that occurs as a complication of medical and surgical diseases, has a mortality of ~40%, and has no known treatment other than optimization of support.
- Trial name
- CHILL-pilot (NCT03376854)
- Testing
- Hypothermia, Neuromuscular Blocking Agents, Standard of Care
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
COVID-19 Associated Cardiac Involvement, Remodeling, Left Ventricle
Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19
Long COVID or Postacute sequelae of COVID-19 infection (PASC) are increasingly recognised complications, defined by lingering symptoms, not present prior to the infection, typically persisting for more than 4 weeks.
- Conditions
- COVID-19 Associated Cardiac Involvement, Remodeling, Left Ventricle, Remodeling, Vascular, Left Ventricular Dysfunction
- Trial name
- MYOFLAME-19 (NCT05619653)
- Testing
- Prednisolone, Losartan
- Where
- 5 sites in Austria, Germany
- Volunteers
- 279 people
- Sponsor
- Valentina Puentmann
Covid19
Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test
Performance of the LumiraDx SARS-CoV-2 Ag assay will be assessed by comparison to a reference method.
- Trial name
- ASPIRE (NCT04557046)
- Testing
- Nasal Swab, Nasopharyngeal swab, Throat swab
- Where
- 7 sites in United States
- Volunteers
- 1,134 people
- Sponsor
- LumiraDx UK Limited
Ventilator Associated Pneumonia, Covid19
Incidence of VAP in Patients With Severe COVID-19
Combined retrospective and prospective cohort study to evaluate the incidence of microbiologically confirmed VAP in mechanically ventilated patients with COVID-19.
- Trial name
- CoV-AP (NCT04766983)
- Testing
- bronchoalveolar lavage
- Where
- Italy
- Volunteers
- 323 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Sars-CoV-2 Infection
Impact of Genetic Polymorphisms of Vasoactive Peptides on the Prognosis of Patients With COVID19
Introduction: A pandemic such as the SRAS-CoV-2 (COVID-19) has a great negative socioeconomic impact with very limited therapeutic options.
- Trial name
- NCT05160779
- Testing
- Analysis of genetic polymorphisms of vasoactive peptides in COVID-19
- Where
- 2 sites in Brazil
- Volunteers
- 151 people
- Sponsor
- Leonardo Paroche de Matos
Covid-19 Disease
A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus
Adult female and male patients, hospitalized with Covid-19 infection (confirmed by reverse transcription polymerase chain reaction [RT-PCR]), will be screened for participation in this prospective, multi-center, double-blind…
- Trial name
- NCT04682873
- Testing
- Enisamium Iodide
- Where
- 13 sites in Ukraine
- Volunteers
- 592 people
- Sponsor
- Joint Stock Company "Farmak"
COVID - 19, Prognosis
The Prognostic Role of Red Blood Cell Distribution (RDW) in Severe COVID-19 Patients
The aim of this study was to evaluate the prognostic significance of erythrocyte distribution width (RDW) in severe and critically ill COVID-19 patients followed in the intensive care unit (ICU).
- Conditions
- COVID - 19, Prognosis, ICU
- Trial name
- RDW-Covıd-19 (NCT07244731)
- Where
- Turkey (Türkiye)
- Volunteers
- 146 people
- Sponsor
- Ankara University
COVID-19, SARS-CoV-2
Treatment for COVID-19 in High-Risk Adult Outpatients
This is a randomized trial for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in high-risk adults not requiring hospital admission.The overarching goal of this study is to assess the…
- Trial name
- NCT04354428
- Testing
- Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin
- Where
- 6 sites in United States
- Volunteers
- 289 people, healthy volunteers welcome
- Sponsor
- University of Washington
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.